About Metsera Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases.

While the year started out as cautiously optimistic, stemming from the peak of biotech initial public offering (IPO) activity ...

Wells Fargo emphasized that Metsera’s long half-life drugs may provide improved tolerability by enabling gradual buildup of drug exposure and avoiding fluctuations that increase adverse events.

Get the latest Metsera, Inc. (MTSR) stock news and headlines to help you in your trading and investing decisions.

Wells Fargo emphasized that Metsera’s long half-life drugs may provide improved tolerability by enabling gradual buildup of drug exposure and avoiding fluctuations that increase adverse events. The ...

Hinge Health and Omada Health reawakened the digital health IPO market. But most late-stage healthcare startups aren't ready to follow them this year.

Fintel reports that on June 20, 2025, Wells Fargo initiated coverage of Metsera (NasdaqGS:MTSR) with a Overweight recommendation. Analyst Price Forecast Suggests 73.01% Upside As of June 2, 2025 ...

Apogee Therapeutics, Inc. (NASDAQ:APGE) is one of the 11 Hot New Stocks to Invest in Now. On July 7, analyst Edward Nash of ...